

2017 TSIBD Summer Forum OPTIMISING OUTCOMES FOR IBD PATIENTS

26 Aug. 2017
新竹喜來登
東館三樓 1、2 廳

Agenda

Aug. 26th (Sat.) 15:00~20:30pm

Time	Title	Faculty	
	Welcome		
PM 15:00- 15:10	Introduction to the meeting		王正一教授 台大醫院內科 楊俊仁 醫師 兒消楊理事長
Session 1: Implementing change in Padiatric CD care			
15:10- 15:35	Burden of paediatric CD – Disease burden – Psychosocial burden	施相宏醫師 高醫小兒科	陳慧玲教授 台大兒童醫院
15:35- 16:00	Treat to target: – How to utilize Biologic therapy to optimize Treat to Target Strategy	Prof. Yon Ho Choe, , Department of Pediatrics Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul, Korea	Prof. 倪衍玄 台大兒童醫院
16:00	Pediatric CD Case Sharing	江椿斌醫師 台北馬偕小兒科	Prof. 賴明璋 林口長庚小兒科
16:25- 16:35	<i>Coffee break</i>		
Session 2: Achieving the full potential of biologic therapy in UC			

TSIBD Summer Forum: OPTIMISING OUTCOMES FOR IBD PATIENTS

16:35-17:00	Optimizing: – Interpreting UC clinical trial data – From clinical trials to clinical practice	Katsuyoshi Matsuoka, M.D. Ph.D. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University	Prof. 吳登強 高醫大附醫腸胃科
17:00-17:25	Defining the time and type of surgical intervention	林春吉醫師 台北榮總大腸直腸外科	Prof. 陳鴻華 高雄長庚直肛科
17:25-17:50	UC Case Sharing	黃天祐醫師 三總腸胃科	Prof. 林楨國 台北榮總大腸直腸外科
17:50-18:00	<i>Coffee break</i>		
Session 3: Enhanced clinical monitoring and patient adherence			
18:00-18:25	Calprotectin – Utilize non-invasive monitoring system to enhance compliance – From Lab. to Home test system	魏淑鈺醫師 台大醫院內科	Prof. 邱正堂 林口長庚腸胃科
18:25-18:50	How Should We Measure Quality Of Care? – Translating theory into practice: Multi-purpose registry by TSIBD	周仁偉醫師 ok 中國醫大附醫腸胃科	Prof. 許自齊 台北馬偕大腸直腸外科
Session 4: Special Lecture			
18:50-19:20	Biosimilar in Rheumatic disease and IBD: hope or expectation?	蔡文展理事長 ok 中華民國風濕病醫學會	Prof. 謝銘鈞 台大醫院內科
19:20-20:00	The association between Hidradenitis Suppurativa and Inflammatory Bowl Disease	台大醫院皮膚部 廖怡華醫師 ok	
20:00-20:20	Panel Discussion		
20:20-20:30	Closing Remark		Prof. 翁昭啟

Curriculum Vitae

1. Personal Information:

Name: Chun-Chi Lin, M.D. (林春吉)

Current position:

2010/7/1~, Attending physician, Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital

2015/2~, Assistant Professor, Faculty of Medicine, National Yang-Ming University

2. Education:

1995/09--2002/06 M.D., National Yang-Ming University, School of Medicine

3. Professional career:

2004/9~, Resident and Chief Resident, Department of Surgery, VGH-Taipei

2009/7~, Clinical Research Fellow, Department of Surgery, VGH-Taipei

2010/3/1~2013/8/30, Attending physician, Department of Medical Research and Education, Taipei Veterans General Hospital

2010/7~, Attending physician, Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital

4. Principal areas of expertise:

Colon & rectal disease

Laparoscopic surgery

5. Professional memberships:

2008~, Member, Taiwan Surgical Association, R.O.C.

2009~, Member, Society of Colon and Rectal Surgeons, Taiwan, R.O.C.

2009~, Member, Taiwan Surgical Society of Gastroenterology, R.O.C.

2010~, Member, Taiwan Association of Medical Education

6. Publication

SCI

1. **Chun-Chi Lin**, Jen-Kou Lin, Shih-Ching Chang, Huann-Sheng Wang, Shung-Haur Yang, Jeng-Kai Jiang, Wei-Shone Chen, Tzu-Chen Lin; Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute. *Int J Colorectal Dis.* 2009 Jun;24(6):665-76. (**first author**)
2. Yen-Ning Hsu, Chia-Jen Liu, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Shung-Haur Yang, Jeng-Kai Jiang, Shih-Ching Chang, Yuan-Tzu Lan, **Chun-Chi Lin**, Chueh-Chuan Yen, Jin-Huang Liu, Cheng-Hwai Tzeng, Hao-Wei Teng; Liver Abscess After Liver Metastasectomy is a Poor Prognostic Factor in Patients with Colorectal Cancer. *J Gastrointest Surg.* 2011 Oct;15(10):1798-806.
3. Jen-Kou Lin, An-Jen Lin, **Chun-Chi Lin**, Yuan-Tzu Lan, Shung-Haur Yang, Anna Fen-Yau Li, Shih-Ching Chang; The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. *J Surg Oncol.* 2011 Jun 13. doi: 10.1002/jso.21993. [Epub ahead of print]
4. Jen-Kou Lin, **Chun-Chi Lin**, Shung-Haur Yang, Huann-Sheng Wang, Jeng-Kai Jiang, Yuan-Tzu Lan, Tzu-Chen Lin, Anna Fen-Yau Li, Wei-Shone Chen and Shih-Ching Chang; Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients

- with curable colorectal cancer. *Int J Colorectal Dis.* 2011 Sep;26(9):1135-41. Epub 2011 May 3. **(first author)**
5. **Lin CC**, Lai YL, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS, Lan YT, Liang WY, Hsu HM, Lin JK, Chang SC.; Clinicopathologic features and prognostic analysis of MSI-high colon cancer. *Int J Colorectal Dis.* 2011 Nov 12. [Epub ahead of print] **(first author)**
 6. Lin JK, Yueh TC, Chang SC, **Lin CC**, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC.; The influence of fecal diversion and anastomotic leakage on survival after resection of rectal cancer. *J Gastrointest Surg.* 2011 Dec;15(12): 2251-61. Epub 2011 Oct 15.
 7. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, **Lin CC**, Hsu YN, Wang HW, Chen KF.; CIP2A is a predictor of poor prognosis in colon cancer. *J Gastrointest Surg.* 2012 May;16(5):1037-47. Epub 2012 Feb 11
 8. Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, **Lin CC**, Yen CC, Tzeng CH, Wang WS, Chiang HL, Teng CJ, Teng HW. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. *Support Care Cancer.* 2012 Jul;20(7):1491-7.
 9. Lin PC, Lin JK, **Lin CC**, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Li AF, Chen WS, Chang SC.; Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. *Int J Colorectal Dis.* 2012 Oct;27(10):1333-8
 10. Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Wang HW, Chang SC, Lan YT, **Lin CC**, Wang HS, Yang SH.; BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. *J Surg Oncol.* 2012 Aug 1;106(2):123-9.
 11. Lin PC, Lin HH, Lin JK, **Lin CC**, Yang SH, Li AF, Chen WS, Chang SC. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence. *Int J Biol Markers.* 2013 Jun 28;28(2):182-6.
 12. Lu YJ, Lin PC, **Lin CC**, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Liang WY, Chen WS, Lin JK, Chang SC. The impact of the lymph node ratio is greater than traditional lymph node status in stage III colorectal cancer patients. *World J Surg.* 2013 Aug;37(8):1927-33.
 13. Shao YC, Chang YY, Lin JK, **Lin CC**, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Li AF, Chen WS, Chang SC. Neoadjuvant chemotherapy can improve outcome of colorectal cancer patients with unresectable metastasis. *Int J Colorectal Dis.* 2013 Oct;28(10):1359-65.
 14. Lin HH, Lin JK, **Lin CC**, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Liang WY, Chang SC. Circumferential margin plays an independent impact on the outcome of rectal cancer patients receiving curative total mesorectal excision. *Am J Surg.* 2013 Nov;206(5):771-7.
 15. Lan YT, Chang SC, Yang SH, **Lin CC**, Wang HS, Jiang JK, Chen WS, Lin TC, Chiou SH, Lin JK. Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. *Am J Surg.* 2013 Nov 10
 16. Huang CS, Lin JK, Wang LW, Liang WY, **Lin CC**, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC. Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer. *Am J Surg.* 2014 Jan 16.
 17. Chang YY, Lin HH, **Lin CC**. Phlebosclerotic Colitis Presenting as Intestinal Obstruction. *Clin Gastroenterol Hepatol.* 2014 Feb 20.
 18. Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, **Lin CC**, Hwang WL, Tzeng CH, Li AF, Yen CC, Teng HW. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. *J Cancer Res Clin Oncol.* 2014 Apr;140(4):561-71.
 19. Yuan Hao Yang, Jen Kou Lin, Wei Shone Chen, Tzu Chen Lin, Shung Haur Yang, Jeng Kai Jiang, Yuan Tzu Lan, **Chun Chi Lin**, Chueh Chuan Yen, Cheng Hwai Tzeng, Hao Wei Teng. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response-a retrospective study. *J Cancer Res Clin Oncol.* 2014 Jun 17. [Epub ahead of print]

20. **Chun-Chi Lin**, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Shung-Haur Yang, Huann-Sheng Wang, Yuan-Tzu Lan, Jeng-Kai Jiang, Muh-Hwa Yang and Shih-Ching Chang. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. *Journal of Surgical Oncology*. 2014 Jun 25. doi: 10.1002/jso.23675. [Epub ahead of print](**first author**)
21. Lin HH, Chang YY, Lin JK, Jiang JK, **Lin CC**, Lan YT, Yang SH, Wang HS, Chen WS, Lin TC, Chang SC. The role of adjuvant chemotherapy in stage II colorectal cancer patients. *Int J Colorectal Dis*. 2014 Jul 15. [Epub ahead of print]
22. Lan YT, Yang SH, Lin JK, **Lin CC**, Wang HS, Chen WS, Lin TC, Jiang JK, Chang SC. Genetic variations are associated with lymph node metastasis in colorectal cancer patients. *J Surg Oncol*. 2014 Sep;110(3):307-12. doi: 10.1002/jso.23613. Epub 2014 Jul 5
23. Lin HH, Lin JK, Jiang JK, **Lin CC**, Lan YT, Yang SH, Wang HS, Chen WS, Lin TC, Liang WY, Chang SC. Clinicopathological analysis of colorectal carcinoid tumors and patient outcomes. *World J Surg Oncol*. 2014 Nov 30;12:366. doi: 10.1186/1477-7819-12-366.
24. Chang CC, Lin HH, Lin JK, **Lin CC**, Lan YT, Wang HS, Yang SH, Chen WS, Lin TC, Jiang JK, Chang SC. FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients. *Int J Biol Markers*. 2014 Nov 12:0. doi: 10.5301/jbm.5000125. [Epub ahead of print]
25. Hung-Ming Chen, Jen-Kou Lin, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Yuan-Tzu Lan, **Chun-Chi Lin**, and Hao-Wei Teng. Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study. *Am J Clin Oncol*. 2014 Oct 20. [Epub ahead of print]
26. Huang SC, Lin JK, Lin TC, Chen WS, Yang SH, Wang HS, Lan YT, **Lin CC**, Jiang JK, Chang SC. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy. *Ann Surg Oncol*. 2015 Jul;22(7):2262-8
27. Liu CJ, Huang N, **Lin CC**, Lee YT, Hu YW, Yeh CM, Chen TJ, Chou YJ. Outcome disparities between medical personnel and nonmedical personnel patients receiving definitive surgery for colorectal cancer: a nationwide population-based study. *Medicine (Baltimore)*. 2015 Jan;94(4):e402
28. Chang YY, Lin JK, Lin TC, Chen WS, Jeng KJ, Yang SH, Wang HS, Lan YT, **Lin CC**, Liang WY, Chang SC. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer. *Hepatology*. 2014 Oct;61(135):1946-53.
29. Liu CJ, Chou YJ, Teng CJ, **Lin CC**, Lee YT, Hu YW, Yeh CM, Chen TJ, Huang N. Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: A nationwide population-based study. *Cancer*. 2015 Aug 15;121(16):2782-90. Epub 2015 Apr 17.
30. Chen KF, Yen CC, Lin JK, Chen WS, Yang SH, Jiang JK, Lan YT, **Lin CC**, Yu HC, Hsu HM, Lin WL, Teng HW. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. *BMC Cancer*. 2015 Apr 17;15:301.
31. Huang CS, Yang SH, **Lin CC**, Lan YT, Chang SC, Wang HS, Chen WS, Lin TC, Lin JK, Jiang JK. Synchronous and metachronous colorectal cancers: distinct disease entities or different disease courses? *Hepatology*. 2015 Mar-Apr;62(138):286-90.
32. Lan YT, Jen-Kou L, Lin CH, Yang SH, **Lin CC**, Wang HS, Chen WS, Lin TC, Jiang JK, Chang SC. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. *J Surg Oncol*. 2015 Jun;111(7):905-10.
33. Lin PC, Lin JK, Lin HH, Lan YT, **Lin CC**, Yang SH, Chen WS, Liang WY, Jiang JK, Chang SC. A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer. *World J Surg Oncol*. 2015 May 20;13:186.
34. Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, **Lin CC**, Liu CA, Teng HW. The Prognostic Role of Para-Aortic Lymph Nodes in Patients with Colorectal Cancer: Is It Regional or Distant Disease? *PLoS One*. 2015 Jun 26;10(6):e0130345.
35. Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, **Lin CC**, Lan YT, Wang

- HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC, Chen MH, Teng HW, Liu JH, Yen CC. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan. *Medicine (Baltimore)*. 2015 Jul;94(26):e1079.
36. Lin HH, Yang HL, Lin JK, **Lin CC**, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Chen WS, Liang WY, Chang SC. The Number of Risk Factors Determines the Outcome Of Stage II Colorectal Cancer Patients. *Hepatogastroenterology*. 2014 Jun;61(132):1024-7.
37. Lan YT, Jiang JK, Chang SC, Yang SH, **Lin CC**, Lin HH, Wang HS, Chen WS, Lin TC, Lin JK. Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams. *Int J Colorectal Dis*. 2015 Dec 10. [Epub ahead of print]

Non-SCI

1. **林春吉(Chun-Chi Lin)**；林楨國(Jen-Kou Lin)；張世慶(Shih-Ching Chang)；王煥昇(Huann-Sheng Wang)；楊純豪(Shung-Haur Yang)；姜正愷(Jeng-Kai Jiang)；陳維熊(Wei-Shone Chen)；林資琛(Tzu-Chen Lin)；Prognostic Value of Oophrectomy in Colorectal Cancer Patients with Ovarian Metastasis. *J Soc Colon Rectal Surgeon (Taiwan) 中華民國大腸直腸外科醫學會雜誌* 20 卷 4 期(2009/12), 94-99
2. 余盈輝(Ying-Hui Yu)；林楨國(Jen-Kou Lin)；林資琛(Tzu-Chen Lin)；陳維熊(Wei-Shone Chen)；姜正愷(Jeng-Kae Jiang)；王煥昇(Huann-Sheng Wang)；張世慶(Shin-Ching Chang)；藍苑慈(Yuan-Tzu Lan)；**林春吉(Chun-Chi Lin)**；楊純豪(Shung-Haur Yang). Impact of Pre-Operative Chemoradiotherapy on cT3N0M0 Middle and Low Rectal Cancer. *J Soc Colon Rectal Surgeon (Taiwan) 中華民國大腸直腸外科醫學會雜誌* 22 卷 3 期 (2011/09), 86-92
3. 林恩光(En-Kwang Lin)；林楨國(Jen-Kou Lin)；林資琛(Tzu-Chen Lin)；陳維熊(Wei-Chone Chen)；姜正愷(Jeng-Kai Jiang)；王煥昇(Huann-Sheng Wang)；張世慶(Shih-Ching Chang)；藍苑慈(Yuan-Tzu Lan)；**林春吉(Chun-Chi Lin)**；楊純豪(Shung-Haur Yang). Risk Factors for Predicting Conversion in Laparoscopic Colorectal Cancer Surgery. *J Soc Colon Rectal Surgeon (Taiwan) 中華民國大腸直腸外科醫學會雜誌* 23 卷 2 期 (2012/06), 57-63
4. 林宏鑫(Hung-Hsin Lin)；**林春吉(Chun-Chi Lin)**；藍苑慈(Yuan-Tzu Lan)；王煥昇(Huann-Sheng Wang)；楊純豪(Shung-Haur Yang)；姜正愷(Jeng-Kai Jiang)；陳維熊(Wei-Shone Chen)；林資琛(Tzu-Chen Lin)；林楨國(Jen-Kou Lin)；張世慶(Shih-Ching Chang). Clinicopathological Differences between Mucinous Adenocarcinoma and Signet-Ring Cell Carcinoma in the Colorectum. *J Soc Colon Rectal Surgeon (Taiwan) 中華民國大腸直腸外科醫學會雜誌* 23 卷 4 期 (2012/12), 151-159
5. 張譽耀(Yu-Yao Chang)；林楨國(Jen-Kou Lin)；林資琛(Tzu-Chen Lin)；陳維熊(Wei-Shone Chen)；楊純豪(Shung-Haur Yang)；王煥昇(Huann-Sheng Wang)；張世慶(Shih-Ching Chang)；藍苑慈(Yuan-Tzu Lan)；**林春吉(Chun-Chi Lin)**；姜正愷(Jeng-Kai Jiang). Hyperammonemic Encephalopathy in Colorectal Cancer Patients Undergoing Chemotherapy. *J Soc Colon Rectal Surgeon (Taiwan) 中華民國大腸直腸外科醫學會雜誌* 24 卷 1 期 (2013/03), 14-20
6. 黃志生(Chih-Sheng Huang)；**林春吉(Chun-Chi Lin)**；藍苑慈(Yuan-Tzu Lan)；楊純豪(Shung-Haur Yang)；王煥昇(Huann-Sheng Wang)；姜正愷(Jeng-Kai Jiang)；陳維熊(Wei-Shone Chen)；林資琛(Tzu-Chen Lin)；林楨國(Jen-Kou Lin)；張世慶(Shin-Ching Chang)；Clinical Relevance of Carbohydrate Antigen 19-9 Level after Chemoradiotherapy in Rectal Cancer Patients with Normal Carcinoembryonic Antigen Level. *中華民國大腸直腸外科醫學會雜誌* 25 卷 3 期 (2014/09), 106-114

7. 盧延榕(Yen-Jung Lu)；**林春吉(Chun-Chi Lin)**；王煥昇(Huann-Sheng Wang)；楊純豪(Shung-Haur Yang)；姜正愷(Jeng-Kai Jiang)；藍苑慈(Yuan-Tzu Lan)；林資琛(Tzu-Chen Lin)；陳維熊(Wei-Shone Chen)；林楨國(Jen-Kou Lin)；張世慶(Shih-Ching Chang)；Adjuvant Chemotherapy for Stage III Colorectal Cancer in Elderly Patients. 中華民國大腸直腸外科醫學會雜誌 26 卷 2 期 (2015/06) , 57-63

出版書籍

1. 跨領域團隊合作照護訓練:課程設計及教案範例; 陳肇文, 黃金洲, 黃加璋, 梁仁峯, **林春吉**, 陳盈如, 程雅琳, 輔導會臺北榮民總醫院, 2011 年 12 月 1 日 ISBN : 9789860291681
2. 臨床教學輕鬆上手: 臨床教學和學習的實用指南; 作者: Judy McKimm;Tim Swanwick. 譯者: 林文玉、**林春吉**、陳素真、陳震寰、梁仁峰、黃志賢、黃金洲、黃加璋、楊令瑀, 合記圖書出版社, 2014 年 3 月 20 日 ISBN13 : 9789861269788